SHINE Technologies has entered into a definitive agreement to acquire the SPECT business from Lantheus, a radiopharmaceutical-focused company, the company announced recently.

Lantheus’ SPECT product portfolio includes imaging agents for the heart, lung, thyroid and bladder.

“Today’s announcement marks a major milestone on our journey to improve lives through fusion technology,” SHINE CEO Greg Piefer said in a statement. “Our companies have a long history of partnership, and we have admired Lantheus’ commitment to ensuring patient access to essential medical radioisotopes. By integrating Lantheus’ SPECT business and talented team with our company, we will expand our product portfolio, accelerate our path to market for our planned suite of isotopes and increase our market share – ultimately ensuring greater access to these life-saving products for patients.”

The combination of SHINE’s fusion-based isotope manufacturing technology with Lantheus’ established market channels will help strengthen SHINE’s leadership in the nuclear medicine market.